Literature DB >> 15175649

CD14 promoter polymorphism -159C>T is associated with susceptibility to chronic Chlamydia pneumoniae infection in peripheral blood monocytes.

J Rupp1, W Goepel, E Kramme, J Jahn, W Solbach, M Maass.   

Abstract

Chlamydia pneumoniae uses peripheral blood monocytes (PBMC) for systemic dissemination and has been linked to atherogenesis by inflammation mediated via TLR2/4 and CD14. We found 12.8% of 610 coronary artery disease (CAD) patients of Central European background to be chronically infected with C. pneumoniae based on the repeated detection of chlamydial DNA in PBMC. Among those the -159C>T CD14 promoter polymorphism was more frequent (OR 1.7, 95% CI 1.08-2.65, P=0.0224) than among C. pneumoniae-negative subjects matched for age and gender. The Arg753Gln TLR2 and Asp299Gly TLR4 polymorphisms were not related to chlamydial infection. Susceptibility for chronic chlamydial infection of PBMC in CAD patients appears associated with the CD14-159C>T promoter polymorphism encoding for enhanced CD14 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175649     DOI: 10.1038/sj.gene.6364112

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  10 in total

1.  Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species.

Authors:  Xiaohui Zhou; Qiangwei Chen; Jessica Moore; Jay K Kolls; Scott Halperin; Jun Wang
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

2.  The CD14 functional gene polymorphism -260 C>T is not involved in either the susceptibility to Chlamydia trachomatis infection or the development of tubal pathology.

Authors:  Sander Ouburg; Joke Spaargaren; Janneke E den Hartog; Jolande A Land; Johan S A Fennema; Jolein Pleijster; A Salvador Peña; Servaas A Morré
Journal:  BMC Infect Dis       Date:  2005-12-20       Impact factor: 3.090

3.  CD14-159C/T polymorphism in the development of delayed skin hypersensitivity to tuberculin.

Authors:  Magdalena Druszczynska; Marcin Wlodarczyk; Grzegorz Kielnierowski; Michal Seweryn; Sebastian Wawrocki; Wieslawa Rudnicka
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

Review 4.  Bench-to-bedside review: Association of genetic variation with sepsis.

Authors:  Ainsley M Sutherland; Keith R Walley
Journal:  Crit Care       Date:  2009-04-29       Impact factor: 9.097

5.  CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients.

Authors:  Ariane Biebl; Axel Muendlein; Zhyrgal Kazakbaeva; Sigrid Heuberger; Gudrun Sonderegger; Heinz Drexel; Susanne Lau; Renate Nickel; Michael Kabesch; Burkhard Simma
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

Review 6.  Pattern recognition receptor-dependent mechanisms of acute lung injury.

Authors:  Meng Xiang; Jie Fan
Journal:  Mol Med       Date:  2009-11-02       Impact factor: 6.354

7.  Monocyte signal transduction receptors in active and latent tuberculosis.

Authors:  Magdalena Druszczynska; Marcin Wlodarczyk; Beata Janiszewska-Drobinska; Grzegorz Kielnierowski; Joanna Zawadzka; Magdalena Kowalewicz-Kulbat; Marek Fol; Piotr Szpakowski; Karolina Rudnicka; Magdalena Chmiela; Wieslawa Rudnicka
Journal:  Clin Dev Immunol       Date:  2013-01-20

Review 8.  Causal inference regarding infectious aetiology of chronic conditions: a systematic review.

Authors:  Sofia Orrskog; Emma Medin; Svetla Tsolova; Jan C Semenza
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

Review 9.  Innate immunogenetics: a tool for exploring new frontiers of host defence.

Authors:  Pierre-Yves Bochud; Murielle Bochud; Amalio Telenti; Thierry Calandra
Journal:  Lancet Infect Dis       Date:  2007-08       Impact factor: 25.071

10.  Relationship between CD14-159C/T gene polymorphism and acute brucellosis risk.

Authors:  Mehdi Moghadampour; Ebrahim Eskandari-Nasab; Fatemeh Shabani
Journal:  Asian Pac J Trop Med       Date:  2016-01-12       Impact factor: 1.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.